j nos pog ny pharmacist ph d unicef msf who geneva 02 november 2004 e mail pogany@axelero hu l.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
IMPROVING ACCESS TO APPROPRIATE PAEDIATRIC ART FORMULATIONS PowerPoint Presentation
Download Presentation
IMPROVING ACCESS TO APPROPRIATE PAEDIATRIC ART FORMULATIONS

Loading in 2 Seconds...

play fullscreen
1 / 34

IMPROVING ACCESS TO APPROPRIATE PAEDIATRIC ART FORMULATIONS - PowerPoint PPT Presentation


  • 342 Views
  • Uploaded on

János Pogány, pharmacist, Ph.D., UNICEF/MSF/WHO , Geneva, 02 November 2004 E-mail: pogany@axelero.hu IMPROVING ACCESS TO APPROPRIATE PAEDIATRIC ART FORMULATIONS Development pharmaceutics – formulation s for paediatric ARVs FIFTH INVITATION FOR EXPRESSION OF INTEREST (EOI)

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'IMPROVING ACCESS TO APPROPRIATE PAEDIATRIC ART FORMULATIONS' - ostinmannual


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
j nos pog ny pharmacist ph d unicef msf who geneva 02 november 2004 e mail pogany@axelero hu
János Pogány, pharmacist, Ph.D.,

UNICEF/MSF/WHO, Geneva, 02 November 2004

E-mail: pogany@axelero.hu

IMPROVING ACCESS TO APPROPRIATE PAEDIATRIC ART FORMULATIONS

Development pharmaceutics

–formulations for paediatric ARVs

Dr. Pogány - WHO, Geneva

fifth invitation for expression of interest eoi

FIFTH INVITATION FOR EXPRESSION OF INTEREST (EOI)

HIV and related diseases

Rev. 27/10/04

nucleoside reverse transcriptase inhibitors
NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
  • Abacavir
  • Didanosine
  • Lamivudine
  • Stavudine
  • Tenofovir
  • Zidovudine

Dr. Pogány - WHO, Geneva

non nucleoside reverse transcriptase inhibitors
NON-NUCLEOSIDE REVERSETRANSCRIPTASE INHIBITORS
  • Efavirenz
  • Nevirapine

Dr. Pogány - WHO, Geneva

protease inhibitors
PROTEASE INHIBITORS
  • Indinavir
  • Lopinavir + Ritonavir Nelfinavir
  • Saquinavir
  • Ritonavir

Dr. Pogány - WHO, Geneva

fixed dose combinations
FIXED DOSE COMBINATIONS
  • Lamivudine + Stavudine
  • Lamivudine + Stavudine + Efavirenz
  • Lamivudine + Stavudine + Nevirapine
  • Lamivudine + Zidovudine
  • Lamivudine + Zidovudine + Efavirenz
  • Lamivudine + Zidovudine + Nevirapine

Dr. Pogány - WHO, Geneva

basic requirements
BASIC REQUIREMENTS

SAFETY (no innovator for FDC-FPPs)

EFFICACY (no innovator for FDC-FPPs)

QUALITY (once safe and effective doses are established, FDC-FPPs can be developed and bioequivalence demonstrated)

Dr. Pogány - WHO, Geneva

potential paediatric applications

POTENTIAL PAEDIATRIC APPLICATIONS

Innovator Antiretroviral Finished Pharmaceutical Products

videx ec 125mg 200mg 250mg and 400mg gastro resistant capsules
Videx EC 125mg, 200mg, 250mg and 400mg Gastro-resistant Capsules
  • Each gastro-resistant capsule, hard contains 125 mg, 200 mg, 250 mg or 400 mg of didanosine.
  • Sodium carmellose, diethyl phthalate, 30% methacrylic acid copolymer dispersion (EUDRAGIT L30D-55), sodium starch glycolate and talc.
  • Capsule shell - gelatin, sodium laurilsulfate, colloidal anhydrous silica and titanium dioxide (E171).
  • Capsule shell imprints (edible ink)shellac, ammonium hydroxide, propylene glycol, simethicone and red iron oxide
  • 2 years
  • Do not store above 25°C.
  • Polyvinyl Chloride/Polyethylene/ACLAR/Aluminium foil blisters

Dr. Pogány - WHO, Geneva

videx ec 125mg 200mg 250mg and 400mg gastro resistant capsules10
Videx EC 125mg, 200mg, 250mg and 400mg Gastro-resistant Capsules

Children: Safety data for children were generally similar to those seen in adults. A higher haematotoxicity has been reported with the combination with zidovudine compared to didanosine monotherapy. Retinal or optic nerve changes have been reported in a small number of children usually at doses above those recommended. It is recommended that children on didanosine treatment undergo dilated retinal examination every 6 months or if a change in vision occurs.

There are no specific pharmacokinetic data from children treated with Videx gastro-resistant capsules.

Dr. Pogány - WHO, Geneva

sustiva 30 mg ml oral solution
SUSTIVA 30 mg/ml oral solution
  • Each millilitre contains 30 mg efavirenz
  • Medium chain triglycerides, benzoic acid (E210) and strawberry/mint flavour.
  • 3 years.
  • The oral solution should be used within one month of first opening the bottle.
  • No special precautions for storage.
  • HDPE bottles with a child-resistant polypropylene closure containing 180 ml of oral solution. An oral syringe with a push-in bottle-neck adapter is included in the carton.

Dr. Pogány - WHO, Geneva

epivir 10 mg ml oral solution
Epivir 10 mg/ml oral solution
  • Oral solution containing 10 mg/ml of lamivudine
  • Sucrose 20 %(3 g/15 ml)
  • Methyl parahydroxybenzoate
  • Propyl parahydroxybenzoate
  • Citric acid Anhydrous
  • Propylene glycol
  • Sodium citrate
  • Artificial strawberry flavour Artificial banana flavour
  • Purified water

Dr. Pogány - WHO, Geneva

epivir 10 mg ml oral solution13
Epivir 10 mg/ml oral solution
  • 2 years
  • Discard the oral solution one month after first opening.
  • Do not store above 25°C.
  • 240 ml oral solution in a white high density polyethylene (HDPE) bottle, with a child resistant closure. A 10 ml polypropylene oral dosing syringe and a polyethylene adapter are also included in the pack.
  • Zeffix oral solution contains 5 mg/ml lamivudine

Dr. Pogány - WHO, Geneva

epivir 10 mg ml oral solution14
Epivir 10 mg/ml oral solution

Children

  • Three months to 12 years of age: the recommended dose is 4 mg/kg twice daily up to a maximum of 300 mg daily.
  • Less than three months of age the limited data available are insufficient to propose specific dosage recommendations (see section 5.2)

Dr. Pogány - WHO, Geneva

viramune 50 mg 5 ml oral suspension
VIRAMUNE 50 mg/5 ml oral suspension
  • Oral suspension containing 10 mg/ml of nevirapine (active substance) as 10.35 mg/ml nevirapine hemihydrate.
  • VIRAMUNE 50 mg/5 ml oral suspension is a white to off-white homogenous suspension.
  • Carbomer, methyl parahydroxybenzoate, propyl parahydroxybenzoate, sorbitol, sucrose, polysorbate 80, sodium hydroxide and purified water.
  • 2 years.
  • The product should be used within 2 months of opening.
  • No special precautions for storage.

Dr. Pogány - WHO, Geneva

viramune 50 mg 5 ml oral suspension16
VIRAMUNE 50 mg/5 ml oral suspension
  • White high density polyethylene (HDPE) bottle with two piece child-resistant closure (outer shell white high density polyethylene, inner shell natural polypropylene) with a low density polyethylene (LDPE) foam liner. Each bottle contains 240 ml of oral suspension.
  • Clear polypropylene 5 ml dispensing syringe with silicone rubber piston seal.
  • Clear low density polyethylene bottle-syringe adapter.

Dr. Pogány - WHO, Geneva

viramune 50 mg 5 ml oral suspension17
VIRAMUNE 50 mg/5 ml oral suspension
  • Infants under the age of 3 months: safety data is available from clinical trials up to 6 weeks of treatment in 179 newborns and infants < 3 months of age (see section 4.6).

Dr. Pogány - WHO, Geneva

viramune 50 mg 5 ml oral suspension18
VIRAMUNE 50 mg/5 ml oral suspension

Patients aged 2 months up to 8 years

  • The recommended dose for patients 2 months up to 8 years is 4 mg/kg once daily for two weeks followed by 7 mg/kg twice daily thereafter. The total daily dose should not exceed 400 mg for any patient.

Patients aged 8 years up to 16 years

  • The recommended dose for patients 8 years up to 16 years is 4 mg/kg once daily for two weeks followed by 4 mg/kg twice daily thereafter. The total daily dose should not exceed 400 mg for any patient.

Dr. Pogány - WHO, Geneva

zerit 200 mg powder for oral solution
Zerit® 200 mg powder for oral solution
  • The reconstituted solution contains 1 mg of stavudine per ml.
  • Cherry flavour Methylparaben Propylparaben
  • Silicon dioxide SimethiconeSodium carmellose
  • Sorbic acid Stearate emulsifiers Sucrose
  • 2 years.
  • After reconstitution with water, store the solution in tightly closed bottles at 2°C to 8°C.
  • HDPE bottle with child resistant screw cap, fill mark (200 ml of solution after constitution) and measuring cup.

Dr. Pogány - WHO, Geneva

retrovir 100 mg 10 ml oral solution
Retrovir® 100 mg/10 ml, oral solution
  • 10 ml of solution contains:Zidovudine 100 mg
  • Retrovir 100mg/10ml oral solution/syrup:
  • A clear, pale yellow, strawberry-flavoured, sugar-free oral solution.
  • The pack contains an oral-dosing syringe which should be fitted to the bottle before use.
  • Maltitol solution GlycerolCitric Acid
  • E211 Sodium Benzoate Saccharin Sodium
  • Flavour Strawberry Flavour White Sugar Purified Water
  • 2 years. Discard oral solution 1 month after first opening bottle.
  • Do not store above 30°C. Store the bottle in the original outer carton.

Dr. Pogány - WHO, Geneva

retrovir 100 mg 10 ml oral solution21
Retrovir® 100 mg/10 ml, oral solution
  • Retrovir Oral Solution/Syrup:
  • 200ml amber glass bottle with a plastic cap and polyethylene wad. A 10ml oral-dosing syringe is included in the pack, with an adaptor, which should be fitted to the bottle before use.
  • Retrovir Oral Solution/Syrup (Neonate Pack):
  • 200ml amber glass bottle with a plastic cap and polyethylene wad. A 1 ml oral-dosing syringe is included in the pack, with an adaptor, which should be fitted to the bottle before use.

Dr. Pogány - WHO, Geneva

combivir f ilm c oated t ablets
Combivir film-coated tablets
  • Each film-coated tablet contains 150 mg lamivudine and 300 mg zidovudine.
  • Tablet core: Microcrystalline cellulose (E460), sodium starch glycollate, colloidal silicon dioxide, magnesium stearate
  • Tablet film coat:Hypromellose (E464), titanium dioxide (E171), macrogol 400, polysorbate 80
  • 2 years
  • Do not store above 30°C
  • Tamper-evident cartons containing opaque polyvinyl chloride/foil blister packs or white high density polyethylene (HDPE) bottle with a child-resistant closure. Each pack type contains 60 film-coated tablets.

Dr. Pogány - WHO, Geneva

trizivir film coated tablets
TRIZIVIR film-coated tablets
  • TRIZIVIR(300mg of abacavir as abacavir sulfate, 150mg lamivudine and 300mg zidovudine) film-coated tablets.
  • Core: microcrystalline cellulose, sodium starch glycollate (type A), magnesium stearate.
  • Coating: Opadry Green 03B11434 containing: hypromellose, titanium dioxide, polyethylene glycol, indigo carmine aluminium lake, iron oxide yellow.
  • 2 years
  • Do not store above 30°C
  • opaque PVC/Aclar blister packs HDPE bottles

Dr. Pogány - WHO, Geneva

innovator paediatric fpps
INNOVATOR PAEDIATRIC FPPs
  • Efavirenz 30mg/ml oral solution
  • Lamivudine 10mg/ml oral solution
  • Nevirapine 50mg/5mloral suspension
  • Stavudine 200mg powder for oral solution
  • Zidovudine 100mg/10ml, oral solution

Dr. Pogány - WHO, Geneva

potential paediatric applications25

POTENTIAL PAEDIATRIC APPLICATIONS

Generic Antiretroviral Finished Pharmaceutical Products

potential paediatric dosage forms for fdc fpps
Potential paediatric dosage forms for FDC-FPPs
  • Powder for oral suspension (priority from pharmaceutical development and stability points of view)
  • Film-coated tablets (priority from economic, pharmaceutical development and stability points of view)
  • Powder for oral solution
  • Chocolate pastilles (expensive and storage/bioavailability may be a problem in tropical climates and hot seasons)

Dr. Pogány - WHO, Geneva

illustrative r d issues
ILLUSTRATIVE R+D ISSUES
  • Key physicochemical characteristics (e.g., water content, solubility, particle size, etc.) of the APIs that can influence the performance of the FPP should be optimized and supported by experimental data.
  • The compatibility of APIs with each other should be studied and the results documented.
  • The compatibility of the APIs with excipients should be documented.

Dr. Pogány - WHO, Geneva

illustrative r d issues28
ILLUSTRATIVE R+D ISSUES

A discriminating dissolution method should be developed for the final composition of the FPP. Limits should be set for each API in fixed-dose FPPs. The dissolution method should be incorporated into the stability and quality control programmes. Multipoint dissolution profiles of both the test and the reference FPPs should be compared.

Dr. Pogány - WHO, Geneva

existing fdc fpps bracketing and matrixing

EXISTING FDC-FPPsBracketing and Matrixing

Multiple strengths of identical or closelyrelated formulations

bracketing
BRACKETING

Examples include but are not limited to

  • tablets of different strengths manufactured by compressing varying amounts ofthe same granulation, and
  • oral solutions/suspensions of different strengths with formulationsthat differ only in minor excipients (e.g., colourants, flavourings).

Dr. Pogány - WHO, Geneva

matrixing
MATRIXING

Examples include but are not limited to

  • tabletsof different strengths manufactured by compressing varying amounts of the samegranulation, and
  • oral solutions/suspensions of different strengths with formulations thatdiffer only in minor excipients (e.g., colourants or flavourings).

Dr. Pogány - WHO, Geneva

smpc and pil
SmPC and PIL
  • The results from pharmacokinetic investigations must be described briefly in the SmPC of the FPP.
  • The SmPC and package insert should be specific with regard to the HIVinfections which can be reasonably treated with the FPP.

Dr. Pogány - WHO, Geneva

conclusions
CONCLUSIONS
  • Safe and effective paediatric doses for FDC-FPPs, SmPCs and PILs should come from (literature survey of) clinical studies.
  • Film-coated tablets and oral solutions or suspensions can be developed in about 18 months, if pre-formulation is started soon.
  • Development can be accelerated if paediatric FDC-FPPs have the same ratio of APIs and compositions are essentially similar to those already registered in the ICH region or prequalified by WHO.

Dr. Pogány - WHO, Geneva